Want to take quizzes and track your credits?
Although spontaneous intraparenchymal hemorrhage (IPH) accounts for less than 20% of cases of stroke, it continues to be associated with the highest mortality of all forms of stroke and substantial morbidity rates.
Early identification and management of IPH is crucial. Blood pressure control, reversal of associated coagulopathy, care in a dedicated stroke unit, and identification of secondary etiologies are essential to optimizing outcomes. Surgical management of hydrocephalus and space occupying hemorrhage in the posterior fossa are accepted forms of treatment. Modern advances in minimally invasive surgical management of primary, supratentorial IPH are being explored in randomized trials. Hemorrhagic arteriovenous malformations and cavernous malformations are surgically excised if accessible, while hemorrhagic dural arteriovenous fistulas and distal/mycotic aneurysms are often managed with embolization if feasible.
Conclusions and Relevance
IPH remains a considerable source of neurological morbidity and mortality. Rapid identification, medical management, and neurosurgical management, when indicated, are essential to facilitate recovery. There is ongoing evaluation of minimally invasive approaches for evacuation of primary IPH and evolution of surgical and endovascular techniques in the management of lesions leading to secondary IPH.
Sign in to take quiz and track your certificates
JN Learning™ from JAMA Network is your new home for CME and MOC from a source you trust. Earn AMA PRA Category 1 CME Credit™ from relevant articles, audio, and Clinical Challenge image quizzes, explore interactives and videos, and – depending on your specialty or state – have your MOC points automatically transferred to the relevant board. Learn more about CME
Corresponding Author: Robert M. Friedlander, MD, Department of Neurological Surgery, University of Pittsburgh Medical Center, 200 Lothrop St, Ste B-400, Pittsburgh, PA 15213 (firstname.lastname@example.org).
Accepted for Publication: February 22, 2019.
Author Contributions: Dr Friedlander had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: All authors.
Acquisition, analysis, or interpretation of data: Gross, Friedlander.
Drafting of the manuscript: Gross.
Critical revision of the manuscript for important intellectual content: All authors.
Administrative, technical, or material support: Jankowitz, Friedlander.
Conflict of Interest Disclosures: Dr Gross is a consultant for Microvention. Dr Jankowitz is a consultant for Medtronic and Stryker Neurovascular and was the co–primary investigator on the ATLAS study. No other disclosures were reported.
You currently have no searches saved.